Benzinga - by Avi Kapoor, Benzinga Staff Writer.
Shares of Oracle Corporation (NYSE: ORCL) rose sharply in today’s pre-market trading after the company reported upbeat earnings for its fiscal third quarter.
Oracle’s third-quarter revenue increased 7% year-over-year to $13.3 billion, which missed the consensus estimate of $13.306 billion, according to Benzinga Pro. The company reported quarterly earnings of $1.41 per share, which beat average estimates of $1.38 per share.
Oracle shares jumped 13.4% to $129.46 in pre-market trading
Here are some other stocks moving in pre-market trading.
Gainers
- Singularity Future Technology Ltd. (NASDAQ: SGLY) gained 88.6% to $5.94 in pre-market trading after gaining over 6% on Monday.
- Nukkleus Inc. (NASDAQ: NUKK) shares rose 87.8% to $2.16 in pre-market trading after surging over 43% on Monday.
- ClearOne, Inc. (NASDAQ: CLRO) rose 74.4% to $1.58 in pre-market trading. ClearOne announced a special one-time cash dividend of 50 cents per share.
- Assure Holdings Corp. (NASDAQ: IONM) gained 49.6% to $0.49 in pre-market trading. Assure Holdings entered into an agreement to sell certain of its assets to MPOWERHealth for up to $4.5 million.
- Gaucho Group Holdings, Inc. (NASDAQ: VINO) climbed 31.4% to $0.71 in pre-market trading.
- Heritage Insurance Holdings, Inc. (NYSE: HRTG) shares gained 24.6% to $8.91 in pre-market trading following better-than-expected fourth-quarter results.
- Nexalin Technology, Inc. (NASDAQ: NXL) shares gained 18.7% to $0.5010 in pre-market trading after falling 12% on Monday. Nexalin Technology recently announced results of a clinical study of its Gen-2 tACS device for the treatment of chronic insomnia.
- ATRenew Inc. (NYSE: RERE) gained 15.1% to $1.37 in pre-market trading after the company reported fourth-quarter results and announced a $20 million share repurchase program.
- MINISO Group Holding Limited (NASDAQ: MNSO) shares gained 15% to $20.61 in pre-market trading after posting stronger-than-expected quarterly earnings.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Losers- Renalytix Plc (NASDAQ: RNLX) fell 19.3% to $0.92 pre-market trading after gaining around 5% on Monday. Renalytix recently received an unsolicited acquisition approach from a large, publicly-listed strategic diagnostics company and is evaluating an acquisition of the entire issued, and to be issued, the share capital of the company.
- CytomX Therapeutics, Inc. (NASDAQ: CTMX) shares dipped 18.3% to $2.05 in pre-market trading following fourth-quarter results.
- ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) fell 17.4% to $19.93 in pre-market trading after the company reported the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia did not meet the primary endpoint.
- Finch Therapeutics Group, Inc. (NASDAQ: FNCH) dipped 16.5% to $2.85 in pre-market trading after jumping over 36% on Monday.
- Snow Lake Resources Ltd. (NASDAQ: LITM) fell 13% to $0.80 pre-market trading after declining around 6% on Monday.
- Solidion Technology Inc. (NASDAQ: STI) fell 12.6% to $1.53 in pre-market trading after jumping 124% on Monday.
- Safe and Green Development Corporation (NASDAQ: SGD) declined 12.1% to $1.02 in pre-market trading after falling over 6% on Monday.
- Kidpik Corp. (NASDAQ: PIK) shares tumbled 10.8% to $4.34 after surging 80% on Monday.
- Marpai, Inc. (NASDAQ: MRAI) shares tumbled 10.2% to $1.76 in pre-market trading after gaining over 11% on Monday. Marpai shares are trading higher after the company reported better-than-expected preliminary Q4 net revenue results. Also, the company announced an "Off-Cycle" new client agreement.
- Ocular Therapeutix, Inc. (NASDAQ: OCUL) shares fell 5.9% to $9.16 in pre-market trading after the company reported worse-than-expected fourth-quarter financial results.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Now Read This: Kohl's, Oracle And 3 Stocks To Watch Heading Into Tuesday
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.